Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson's Disease

NCT04658186 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT04658186
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04658186 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson's Disease
Lead sponsor
UCB Biopharma SRL
Phase
Phase 2
Overall status
Completed
Start date
December 30, 2020
Completion date
September 6, 2024
Enrollment
496 (actual)
Sites
115

Conditions

As the registry lists them; a condition with its own page is linked.

early-stage parkinson's disease